Falling coronavirus cases in Japan cause delay in Avigan clinical tests

Fujifilm Holdings Corp. will continue clinical tests of its anti-flu drug Avigan, a candidate treatment for the novel coronavirus, beyond the initially scheduled end in June due to a lack of sufficient data, a company source said Monday.Fujifilm planned to finish the clinical tests it started in March in Japan by the end of this month but has seen a delay as recent falls in the number of confirmed infections made it difficult to reach the enrollment target of 96 patients, the source said.Fujifilm said it does not know when the clinical tests of the drug, developed by its unit Fujifilm Toyam…READ FULL ARTICLE